Erratum to "Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists" [Bioorg. Med. Chem. Lett. 16 (2006) 989-994] (DOI:10.1016/j.bmcl.2005.10.087);Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl] piperidine series of histamine H3 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 4, 2006, Pages 989-994

  Berlin, Michael ^a   Ting, Pauline C ^a   Vaccaro, Wayne D ^a,b   Aslanian, Robert ^a   McCormick, Kevin D ^a   Lee, Joe F ^a   Albanese, Margaret M ^a   Mutahi, Mwangi W ^a   Piwinski, John J ^a   Shih, Neng Yang ^a   Duguma, Luli ^a   Solomon, Daniel M ^a   Zhou, Wei ^a   Sher, Rosy ^a   Favreau, Leonard ^a   Bryant, Matthew ^a   Korfmacher, Walter A ^a   Nardo, Cymbelene ^a   West Jr , Robert E ^a   Anthes, John C ^a   Williams, Shirley M ^a   Wu, Ren Long ^a   Susan She, H ^a   Rivelli, Maria A ^a   Corboz, Michel R ^a   Hey, John A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

4 (1H imidazol 4 yl) methyl piperidine; Allergic rhinitis; CYP450 inhibition; Decongestion; H3 antagonists; Histamine; Imidazole series

Indexed keywords

4 [(1H IMIDAZOL 4 YL)METHYL]PIPERIDINE; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; HISTAMINE H3 RECEPTOR ANTAGONIST; IMIDAZOLE; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BIOAVAILABILITY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL ANIMAL; NONHUMAN;

ANIMALIA;

EID: 30344443374     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.01.096     Document Type: Erratum

References (13)

1. M. Murray Drug Metab. Rev. 18 1987 55
2. R. Yang, J. Hey, R. Aslanian, and C. Rizzo Pharmacology 66 2002 128
3. J.R. Halpert, F.P. Guengerich, J.R. Bend, and M.A. Correia Toxicol. Appl. Pharmacol. 125 1994 163
4. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. Guengerich J. Pharmacol. Exp. Ther. 270 1994 414
5. F. Guengerich J. Pharmacokinet. Biopharm. 24 1996 521
6. J. Lin, and A. Lu Pharmacol. Rev. 49 1997 403
7. 3 antagonists structurally analogous to compound 1 was described R. Apodaca, C. Dvorak, W. Xiao, A. Barbier, J. Boggs, S. Wilson, T. Lovenberg, and N. Carruthers J. Med. Chem. 46 2003 3938
8. R. West, A. Zweig, N.-Y. Shih, M. Siegel, R. Egan, and M. Clark Mol. Pharmacol. 38 1990 610
9. R. McLeod, C. Rizzo, R. West, R. Aslanian, K. McCormick, M. Bryant, Y. Hsieh, W. Korfmacher, G. Mingo, L. Varty, S. Williams, N.-Y. Shih, R. Egan, and J. Hey J. Pharm. Exp. Therap. 305 2003 1037
10. L. Favreau, J. Palamanda, C. Lin, and A. Nomeir Drug Metab. Disp. 27 1999 436 and references therein
11. J. Palamanda, L. Favreau, C. Lin, and A. Nomeir Drug Disc. Today 10 1998 466
12. Interestingly, CYP2D6 profile of meta-substituted analogs, while inferior to that of 4, appears to be much less sensitive to the presence of basic nitrogen or lack thereof (see 15 vs 5 compared to 14 vs 4).
13. See preceding paper.